Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Eye Drop for Eye Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 10 years of age~* positive history of ocular allergies~* positive skin test reaction to allergens.~Exclusion Criteria:~* known allergy, contraindication, or sensitivities to the use of any of the study medication(s) or their components~* ocular surgical intervention within three (3) months prior to visit 1 or during the study~* known history of retinal detachment, diabetic retinopathy, or progressive retinal disease, or glaucoma~* any other significant illness

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- alcaftadine ophthalmic solution (Type: EXPERIMENTAL): active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
- inactive ophthalmic solution vehicle (Type: PLACEBO_COMPARATOR): Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).

Based on this trial design, predict the completion outcome and termination type (if applicable).